Go to home page - PHARMAC - Pharmaceutical Management Agency
Leading Edge Medicines Management home
Patients & Consumers Health Professionals District Health Boards Pharmaceutical Suppliers

Fri Feb 10 2012 NZST

RSSRSS feed (help and list of feeds)

Consultation

We ask for feedback on proposals through public consultation, and take into account all consultation responses we receive before making our decisions. PHARMAC has published guidance for consumers on getting involved in our decisions, and this includes responses to consultation. You can download the document here (8 pages, 100 KB).

We welcome feedback from pharmaceutical suppliers, health professionals, health interest groups and the general public. This page includes consultations that are currently underway.

You can respond to a consultation by writing to the address at the bottom of the consultation letter. Notifications of the outcomes of closed consultations are available here.

Rapid response

If you would like to make a rapid response to any of our consultations, click here. Remember to indicate which consultation proposal your comments relate to.

Search for previous consultation documents

Page updated on 09 Feb 2012


Linked documents

page1

Having Your Say in our Decisions (8 pages, 100 KB)
Pharmaceutical Management Agency Having your say in our decisions PHARMAC’s decision-making PHARMAC is the Government agency that decides which medicines are funded for New Zealanders. We welcome input from people into our decision-making processes. There are a number of ways…

text


page1

Amend restrictions relating to various ophthalmology products; Closing Date: Wednesday 22 February 2012; Contact: Greg Williams (3 pages, 158 KB)
3 February 2012 Proposal to amend restrictions relating to various ophthalmology products. PHARMAC is seeking feedback on proposals to remove the prescribing guidelines currently in Part B of the Pharmaceutical Schedule for glaucoma preparations and to include several ophthalmology products…

text


page1

Proposal to fund lapatinib and pazopanib and amend funding criteria for trastuzumab; Closing Date: 5pm, Thursday 9 February 2012; Contact: Jackie Evans (7 pages, 154 KB)
26 January 2012 Proposal to fund lapatinib and pazopanib and amend funding criteria for trastuzumab PHARMAC is seeking feedback on a proposal to:  Fund lapatinib (Tykerb) as an alternative to trastuzumab (Herceptin) for the first line treatment of patients…

text


page1

Widen access to ursodeoxycholic acid; Closing Date: Closed; Contact: Natalie Davis (2 pages, 126 KB)
20 January 2012 Proposal to widen access to ursodeoxycholic acid PHARMAC is seeking feedback on a proposal to widen funded access to ursodeoxycholic acid for prevention of veno-occlusive disease in patients receiving high dose conditioning therapy prior to bone marrow…

text


page1

Proposal to fully fund Symbicort Turbuhaler and Vannair; Closing Date: Closed; Contact: Christine Chapman (3 pages, 127 KB)
17 January 2012 Proposal to fully fund Symbicort Turbuhaler and Vannair PHARMAC is seeking feedback on a proposal to fully subsidise budesonide with eformoterol (Symbicort Turbuhaler and Vannair) from 1 March 2012 through a provisional agreement with AstraZeneca. In summary,…

text


page1

Proposal to amend the listing of benztropine mesylate injections; Closing Date: Closed; Contact: Natalie Davis (2 pages, 110 KB)
5 December 2011 Proposal to amend the listing of benztropine mesylate injections PHARMAC has signed a provisional agreement with Invida Australia Pty Ltd and is seeking feedback on the following proposals relating to benztropine mesylate (Cogentin) injections:  benztropine mesylate…

text


page1

Feedback on draft Records Retention and Disposal Schedule; Closing Date: Closed; Contact: Davina Carpenter (1 page, 79 KB)
28 November 2011 Feedback on draft Records Retention and Disposal Schedule PHARMAC is seeking feedback on our records retention and disposal schedule and the report that must accompany the schedule when it is submitted to Archives New Zealand. In summary,…

text


page1

List Jaychem's Chlorhexidine in Alcohol in Section H; Closing Date: Closed; Contact: Andrew Davies (1 page, 106 KB)
21 November 2011 Proposal to list Jaychem’s Chlorhexidine in Alcohol in Section H of the Pharmaceutical Schedule PHARMAC and Jaychem Industries Ltd have entered into a provisional agreement for chlorhexidine in alcohol. This proposal would result in a 500 ml…

text


page1

Candesartan - Access widening and sole supply; Closing Date: Closed; Contact: Stephen Woodruffe (3 pages, 108 KB)
27 October 2011 Candesartan - Special Authority Removal and Sole Supply PHARMAC is seeking feedback on the following proposals relating to candesartan following a Request for Proposals issued in September 2011. In summary, these proposals would result in: Price and…

text


page1

Proposal for the funding of an additional brand of adrenaline injection; Closing Date: Closed; Contact: Stephen Woodruffe (1 page, 133 KB)
18 October 2011 Proposal for the funding of an additional brand of adrenaline (1:10,000) injection Proposal summary PHARMAC and Aspen Pharmacare Australia Pty Limited have entered into a provisional agreement for Aspen’s adrenaline injection 1 in 10,000, 10 ml (Aspen…

text


page1

Proposal for sole supply of Respiratory Devices; Closing Date: Closed; Contact: Christine Chapman (3 pages, 149 KB)
14 October 2011 Proposal for sole supply of Respiratory Devices (peak flow meters, spacer devices, paediatric masks) As a result of a request for proposals (RFP) for the sole supply of peak flow meters, spacer devices and paediatric masks for…

text


page1

Proposal to amend the rules relating to Discretionary Community Supply; Closing Date: Closed; Contact: Sean Dougherty (2 pages, 108 KB)
13 October 2011 Proposal to amend the rules relating to Discretionary Community Supply PHARMAC is seeking feedback on a proposal to widen the circumstances under which DHB hospitals can provide non-DCS Pharmaceuticals to patients for use in the community without…

text


page1

Proposal to cease Schedule publication in Microsoft Access format; Closing Date: Closed; Contact: John Geering (2 pages, 125 KB)
11 October 2011 Proposal to Cease Schedule publication in Microsoft Access format PHARMAC is seeking feedback on a proposal to reduce the number of formats in which the Pharmaceutical Schedule is published. In particular it is proposed to cease publication…

text


page1

Amending access criteria for lignocaine containing urethral syringes; Closing Date: Closed; Contact: Geraldine MacGibbon (1 page, 101 KB)
3 October 2011 Proposal to amend the access criteria for lignocaine-containing urethral syringes PHARMAC is seeking feedback on a proposal to add an endorsement restriction to the listings of lignocaine gel 2%, 10 ml urethral syringe (Pfizer) and lignocaine gel…

text


page1

Sole supply of metoprolol; Closing Date: Closed; Contact: Stephen Woodruffe (3 pages, 99 KB)
30 September 2011 Sole Supply of Metoprolol Succinate and Metoprolol Tartrate PHARMAC is seeking feedback on the following sole supply proposals for metoprolol succinate (tablets) and metoprolol tartrate (tablets and injection) arising from our Request for Proposals for these products…

text


page1

Proposal relating to risperidone and quetiapine; Closing Date: Closed; Contact: Geraldine MacGibbon (2 pages, 115 KB)
23 September 2011 Proposal to re-apply reference pricing across brands of risperidone and quetiapine PHARMAC is seeking feedback on a proposal to re-apply reference pricing across different brands of risperidone tablets and oral liquid and across different brands of quetiapine…

text


page1

Consultation on provisional agreement with CSL Biotherapies; Closing Date: Closed; Contact: Greg Williams (3 pages, 133 KB)
22 September 2011 Proposal relating to betamethasone diproprionate with calcipotriol, calcipotriol, fusidic acid and bumetanide. PHARMAC is seeking feedback on a proposal to fund betamethasone diproprionate with calcipotriol (Daivobet) through a provisional agreement with CSL Biotherapies (NZ) Limited. This proposal…

text


page1

Proposal to amend the terms of listing for efavirenz; Closing Date: Closed; Contact: Greg Williams (1 page, 110 KB)
22 September 2011 Proposal to amend the terms of listing for efavirenz Following a request to pharmaceutical suppliers for commercial proposals as an alternative to tendering certain pharmaceuticals for sole supply, PHARMAC and Merck Sharp and Dohme (New Zealand) Limited…

text


page1

Proposal relating to four opthalmological products; Closing Date: Closed; Contact: Sue Anne Yee (2 pages, 125 KB)
14 September 2011 Proposal relating to bimatoprost, brimonidine tartrate with timolol maleate and prednisolone acetate PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Allergan Australia Pty Ltd for four ophthalmological products. In summary, this proposal…

text


page1

Proposal on subsidy changes and access for some respiratory products; Closing Date: Closed; Contact: Christine Chapman (5 pages, 149 KB)
30 August 2011 Proposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers. As notified on 16 June 2011, PHARMAC has been considering options for managing the funding of the inhaled corticosteroids (ICS) and long-acting…

text


page1

Proposal to amend General Rules in the Pharmaceutical Schedule; Closing Date: Closed; Contact: Rebecca Bloor (6 pages, 145 KB)
19 August 2011 Proposal to amend the General Rules in the Pharmaceutical Schedule PHARMAC is seeking feedback on a proposal to amend the General Rules in the Pharmaceutical Schedule. The intention of this proposal is to reduce some of the…

text